Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach

A major challenge in translating genomic variants of Tuberculosis (TB) into clinical implementation is to integrate the disease-associated variants and facilitate drug discovery through the concept of genomic-driven drug repurposing. Here, we utilized two established genomic databases, namely a Geno...

Full description

Bibliographic Details
Main Authors: Lalu Muhammad Irham, Wirawan Adikusuma, Dyah Aryani Perwitasari
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Biochemistry and Biophysics Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405580822001340
_version_ 1828365576461877248
author Lalu Muhammad Irham
Wirawan Adikusuma
Dyah Aryani Perwitasari
author_facet Lalu Muhammad Irham
Wirawan Adikusuma
Dyah Aryani Perwitasari
author_sort Lalu Muhammad Irham
collection DOAJ
description A major challenge in translating genomic variants of Tuberculosis (TB) into clinical implementation is to integrate the disease-associated variants and facilitate drug discovery through the concept of genomic-driven drug repurposing. Here, we utilized two established genomic databases, namely a Genome-Wide Association Study (GWAS) and a Phenome-Wide Association Study (PheWAS) to identify the genomic variants associated with TB disease and further utilize them for drug-targeted genes. We evaluated 3.425 genomic variants associated with TB disease which overlapped with 200 TB-associated genes. To prioritize the biological TB risk genes, we devised an in-silico pipeline and leveraged an established bioinformatics method based on six functional annotations (missense mutation, cis-eQTL, biological process, cellular component, molecular function, and KEGG molecular pathway analysis). Interestingly, based on the six functional annotations that we applied, we discovered that 14 biological TB risk genes are strongly linked to the deregulation of the biological TB risk genes. Hence, we demonstrated that 12 drug target genes overlapped with 40 drugs for other indications and further suggested that the drugs may be repurposed for the treatment of TB. We highlighted that CD44, CCR5, CXCR4, and C3 are highly promising proposed TB targets since they are connected to SELP and HLA-B, which are biological TB risk genes with high systemic scores on functional annotations. In sum, the current study shed light on the genomic variants involved in TB pathogenesis as the biological TB risk genes and provided empirical evidence that the genomics of TB may contribute to drug discovery.
first_indexed 2024-04-14T05:33:02Z
format Article
id doaj.art-9c0d7473e14c4548a5ad532ec78a2f80
institution Directory Open Access Journal
issn 2405-5808
language English
last_indexed 2024-04-14T05:33:02Z
publishDate 2022-12-01
publisher Elsevier
record_format Article
series Biochemistry and Biophysics Reports
spelling doaj.art-9c0d7473e14c4548a5ad532ec78a2f802022-12-22T02:09:44ZengElsevierBiochemistry and Biophysics Reports2405-58082022-12-0132101334Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approachLalu Muhammad Irham0Wirawan Adikusuma1Dyah Aryani Perwitasari2Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, IndonesiaDepartment of Pharmacy, University of Muhammadiyah Mataram, Mataram, IndonesiaFaculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia; Corresponding author.A major challenge in translating genomic variants of Tuberculosis (TB) into clinical implementation is to integrate the disease-associated variants and facilitate drug discovery through the concept of genomic-driven drug repurposing. Here, we utilized two established genomic databases, namely a Genome-Wide Association Study (GWAS) and a Phenome-Wide Association Study (PheWAS) to identify the genomic variants associated with TB disease and further utilize them for drug-targeted genes. We evaluated 3.425 genomic variants associated with TB disease which overlapped with 200 TB-associated genes. To prioritize the biological TB risk genes, we devised an in-silico pipeline and leveraged an established bioinformatics method based on six functional annotations (missense mutation, cis-eQTL, biological process, cellular component, molecular function, and KEGG molecular pathway analysis). Interestingly, based on the six functional annotations that we applied, we discovered that 14 biological TB risk genes are strongly linked to the deregulation of the biological TB risk genes. Hence, we demonstrated that 12 drug target genes overlapped with 40 drugs for other indications and further suggested that the drugs may be repurposed for the treatment of TB. We highlighted that CD44, CCR5, CXCR4, and C3 are highly promising proposed TB targets since they are connected to SELP and HLA-B, which are biological TB risk genes with high systemic scores on functional annotations. In sum, the current study shed light on the genomic variants involved in TB pathogenesis as the biological TB risk genes and provided empirical evidence that the genomics of TB may contribute to drug discovery.http://www.sciencedirect.com/science/article/pii/S2405580822001340BioinformaticsDrug repurposingDrug discoveryGenomic variantsTuberculosis
spellingShingle Lalu Muhammad Irham
Wirawan Adikusuma
Dyah Aryani Perwitasari
Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach
Biochemistry and Biophysics Reports
Bioinformatics
Drug repurposing
Drug discovery
Genomic variants
Tuberculosis
title Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach
title_full Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach
title_fullStr Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach
title_full_unstemmed Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach
title_short Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach
title_sort genomic variants driven drug repurposing for tuberculosis by utilizing the established bioinformatic based approach
topic Bioinformatics
Drug repurposing
Drug discovery
Genomic variants
Tuberculosis
url http://www.sciencedirect.com/science/article/pii/S2405580822001340
work_keys_str_mv AT lalumuhammadirham genomicvariantsdrivendrugrepurposingfortuberculosisbyutilizingtheestablishedbioinformaticbasedapproach
AT wirawanadikusuma genomicvariantsdrivendrugrepurposingfortuberculosisbyutilizingtheestablishedbioinformaticbasedapproach
AT dyaharyaniperwitasari genomicvariantsdrivendrugrepurposingfortuberculosisbyutilizingtheestablishedbioinformaticbasedapproach